Home Cart Sign in  
Chemical Structure| 960404-48-2 Chemical Structure| 960404-48-2

Structure of 960404-48-2

Chemical Structure| 960404-48-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dapagliflozin propanediol is an inhibitor of SGLT2 that is used for the treatment of of type 2 diabetes mellitus.

Synonyms: BMS-512148 (2S)-1,2-propanediol, hydrate; Dapagliflozin propanediol monohydrate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dapagliflozin ((2S)-1,2-propanediol, hydrate)

CAS No. :960404-48-2
Formula : C24H35ClO9
M.W : 502.98
SMILES Code : CCOC1=CC=C(CC2=C(Cl)C=CC([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)=C2)C=C1.OC[C@@H](O)C.O
Synonyms :
BMS-512148 (2S)-1,2-propanediol, hydrate; Dapagliflozin propanediol monohydrate
MDL No. :MFCD28167768
InChI Key :GOADIQFWSVMMRJ-UPGAGZFNSA-N
Pubchem ID :24906252

Safety of Dapagliflozin ((2S)-1,2-propanediol, hydrate)

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human coronary artery endothelial cells (HCAECs) 10 µM 24 hours Dapagliflozin improved endothelial barrier function, eNOS activity, and angiogenic capacity in H/R-challenged HCAECs, and inhibited H/R-induced apoptosis by preventing cofilin-dependent F-actin depolymerization and cytoskeletal degradation. PMC9274739
HK-2 cells 10 µM 48 hours To evaluate the protective effect of Dapagliflozin on UA-induced injury in HK-2 cells, results showed that Dapagliflozin significantly reduced UA-induced fibrotic changes and improved mitochondrial function. PMC11384938
rat vascular smooth muscle cells 5 μM, 10 μM, 20 μM 14 days DAPA significantly attenuated VSMC calcification, as shown by Alizarin red staining and von Kossa staining. PMC11127605
human vascular smooth muscle cells 10 μM 14 days Similar inhibitory effects of DAPA on calcification were observed in human VSMCs. PMC11127605

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Cardiac ischemia/reperfusion injury model Intraperitoneal injection 0.5 g/kg/day Once daily for 8 weeks Dapagliflozin pretreatment attenuated luminal stenosis, endothelial swelling, and inflammation in cardiac microvessels of IRI-treated mice. PMC9274739
Mice Hyperuricemic nephropathy model Oral 50 mg/kg Twice daily for 7 days To evaluate the effect of Dapagliflozin on renal function and fibrosis in hyperuricemic nephropathy mice, results showed that Dapagliflozin significantly improved renal function and reduced renal fibrosis. PMC11384938
mice vitamin D3 overdose-induced calcification model oral 15 mg/kg/day once daily for 6 weeks DAPA significantly attenuated aortic calcium deposition, as evidenced by Alizarin Red staining, von Kossa staining, alkaline phosphatase (ALP) activity and calcium content assays. PMC11127605
Mice Heart failure with preserved ejection fraction (HFpEF) model Mixed with high-fat diet chow 65 mg/kg Once daily for three weeks Dapa improved glucose handling but had mild effects on the HFpEF phenotype PMC8318109

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.94mL

1.99mL

0.99mL

19.88mL

3.98mL

1.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories